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Abstract
Background: Genome variability of host genome and cancer cells play critical role in diversity of response to
existing therapies and overall success in treating oncological diseases. In chronic myeloid leukemia targeted therapy
with tyrosine kinase inhibitors demonstrates high efficacy in most of the patients. However about 15 % of patients
demonstrate primary resistance to standard therapy. Whole exome sequencing is a good tool for unbiased search
of genetic variations important for prognosis of survival and therapy efficacy in many cancers. We apply this
approach to CML patients with optimal response and failure of tyrosine kinase therapy.
Results: We analyzed exome variations between optimal responders and failures and found 7 variants in cancer-
related genes with different genotypes in two groups of patients. Five of them were found in optimal responders:
rs11579366, rs1990236, rs176037, rs10653661, rs3803264 and two in failures: rs3099950, rs9471966. These variants
were found in genes associated with cancers (ANKRD35, DNAH9, MAGEC1, TOX3) or participating in cancer-related
signaling pathways (THSD1, MORN2, PTCRA).
Conclusion: We found gene variants which may become early predictors of the therapy outcome and allow
development of new early prognostic tests for estimation of therapy efficacy in CML patients. Normal genetic
variation may influence therapy efficacy during targeted treatment of cancers.
Keywords: Genetic variation, Chronic myeloid leukemia, TKI resistance, Whole exome sequencing, Biomarkers,
Prognostic factors
Background
Chronic myeloid leukemia (CML) accounts for about 10 %
of all leukemias. The primary mutation in blood stem cell is
induced by the translocation between chromosomes 9 and
22 leading to the formation of the so-called Philadelphia
chromosome (Ph+) – an aberrant chromosome 22. As a
result of this translocation two genes are fused: ABL
(chromosome 9) and BCR (chromosome 22) [1]. BCR/ABL
gene produces atypical tyrosine kinase – BCR/ABL which
activates MAPK pathway and induces cell proliferation,
blocks apoptosis and leads to genome instability resulting
in further development of the disease.
Till late 1990s the prognosis for the patients with CML
was poor. The disease progressed gradually to the acceler-
ated phase, blast crisis and finally death. Invention of BCR/
ABL tyrosine kinase inhibitor (TKI) made the disease well
controlled and dramatically improved patient’s survival.
The first TKI – imatinib – has become the standard
therapy of CML since its FDA approval in 2001. Patient’s
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survival considerably improved from 7.5 years after diagno-
sis before imatinib invention to 17.5 years now-a-days [2].
However some patients still remain resistant to TKI therapy.
The rate of primary resistance is in the range of 5–20 % [3,
4]. According to ELN recommendations 2013 [5] CML
patients on TKI therapy are assigned to optimal responders,
failures and “warning” group. Optimal responders may con-
tinue the same treatment, failures need treatment changes,
“warning” group needs careful observation with the readi-
ness to change treatment options. Currently available prog-
nostic scores – Sokal and EUTOS may help to predict
patients with worse clinical outcome on TKIs although some
studies failed to demonstrate predictive value of EUTOS
score for different clinical outcomes including long-term
overall survival rate [6, 7]. Therefore additional clinically
relevant prognostic markers for CML patients are extremely
important. High genetic variability of cancer cells in CML is
difficult for analysis and selection of prognostic markers.
In this work we perform whole exome sequencing
(WES) of newly diagnosed CML patients and analyze
exomic variations which can serve as early predictive
markers of the high and low efficacy of TKI therapy.
Results
Characteristics of the patients
Twenty three patients were available with follow-up data at
6 months after beginning TKI treatment (11 males and 12
females; mean age – 42.4 years). Two patients (8.7 %) were
classified as failures, 7 patients (30.4 %) were assigned to
warning group and other 14 patients demonstrated optimal
response according to ELN recommendations 2013. Blood
samples from 8 patients were taken for further analysis: 4
optimal responders and 4 patients with TKI inefficacy (2
failures and 2 patients from the warning group). Frontline
therapy was imatinib in 3 optimal responders and 3 non
responders, and nilotinib in 1 responder and 1 non
responder. Two failures were switched to nilotinib and
dasatinib after 2.5 and 4 months of imatinib therapy. The
detailed description of the patients included in the study is
available in the Additional file 1: Table S1. Blood samples
were drawn before starting TKI therapy when vast majority
of nucleated blood cells were leukemic. Paired blood sam-
ples were drawn from 3 optimal responders after 6 months
of TKI therapy during relapse for analysis of normal
exomes. All 11 blood samples were sequenced.
Whole exome sequencing
In total about 55 millions of nucleotides in targeted se-
quences were covered in average 20×. Sequences were
aligned to hg19. Ion Torrent Variant Caller plugin was
used to call variants. In each of 11 samples we found
from 33,657 to 38,636 homo- and heterozygous variants
(SNVs), including single nucleotide variants and inser-
tions and deletions. All the variations are available at
European Nucleotide Archive (http://www.ebi.ac.uk/ena/
data/view/PRJEB9857). There were about 5300 unique
variants in each sample. All 116,508 variants were merged
in one table for further annotation and analysis. Variants
were found in 17,741 genes. In each gene we found from
at least one variant in one or more samples up to 345 vari-
ants (MUC16). The full list of genes with number of found
variants is available in Additional file 2: Table S2. Pathway
enrichment analysis using Gorilla (ver. Mar 28, 2015) [8]
revealed possibly damaged by SNVs cellular pathways:
antigen processing and presentation of endogenous pep-
tide antigen via MHC class I via ER pathway, TAP-
independent (p = 1.8 × 10−7), interferon-gamma-mediated
signaling pathway (p = 9.6 × 10−8) and O-glycan processing
(p = 1.9 × 10−13); functions: peptide antigen binding (p =
1.8 × 10−10), MHC class II receptor activity (p = 2.1 × 10−7);
and structures: MHC protein complex (p = 3.7 × 10−11),
integral component of lumenal side of endoplasmic
reticulum membrane (p = 5.2 × 10−11), Golgi lumen (p =
5 × 10−13) and ER to Golgi transport vesicle membrane
(p = 7.7 × 10−10). The full list of the enrichment ana-
lysis results is available in Additional file 1: Table S3.
Variant analysis
We were looking for variants which were present in all
samples of one group and absent in all samples from the
opposite group. We performed such a filtering for optimal
responders and for the failures separately. In leukemic cells
of all four optimal responder we found 11 333 variants in
total. These variants included both homozygous and het-
erozygous SNPs. 152 of them were not present in either of
leukemic samples from patients with failure of the
response. We further filtered missense and splice-site vari-
ants and also variants in regulatory regions and we got only
27 variants. By manual verification of sequenced reads in
IGV browser [9, 10] we confirmed 21 variant. Based on
GeneCards descriptions (available in October, 2014) we se-
lected 11 variants in genes known to be associated with
cancers (ANKRD35 – rs11579366, ATP7B – rs732774,
COSM147691, IGHV4-31 – rs61995642, ANPEP – rs25651,
DNAH9 – rs1990236, CCDC165 – rs632423, MAGEC1 –
rs176037) or cancer-associated pathways like MAPK
(FCRL3 – rs7522061, LRP2 – rs2229263, KLB – rs4975017)
or cellular processes frequently deteriorated in cancer like
DNA integrity control (FANCD2 – rs3864017). We selected
3 variants (ANKRD35 – rs11579366, DNAH9 – rs1990236,
MAGEC1 – rs176037) positive for either SIFT [11] or Poly-
Phen [12] score to validate them with Sanger sequencing.
We also selected additional variant previously not de-
scribed in dbSNP135 which we confirmed manually with
IGV browser. It was in breast cancer associated TOX3
(rs10653661 according to dbSNP141). This variant was
also selected for confirmation by Sanger sequencing.
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Another filtering option was to select only homozy-
gotes in all 4 optimal responders. Two out of 10 of them
were confirmed by manual verification. One of them
was annotated in the gene involved in angiogenesis,
apoptosis, activation of TGF-beta (THSD1 – rs3803264),
and was also selected.
We applied exactly the same filtering pipe-line to the
set of data from leukemic cells in the group of failures.
We found 8 969 variants in all four failures. Only 51 of
them were not present in optimal responders. Filtering
missense and spice-site variants left 15 variants. We
verified manually 7 variants. GeneCards annotations did
not allow to perform any specific filtering based on the
gene functions – some genes seem to play important role
in RNA metabolism (DHX37 – rs11558556), cell growth
and proliferation (ADRA1A – rs1048101, CM064954) or
immune system (PTCRA – rs9471966) and little is known
about others (KIAA0226L – rs1408184, CCDC11 –
rs35193847, MORN2 – rs3099950, TMX4 – rs2294248).
Two variants (MORN2 – rs3099950, PTCRA – rs9471966)
with deleterious/damaging effect according to SIFT or
PolyPhen were selected for further Sanger sequencing.
Scheme of all filtering steps is available in Additional
file 1: Figure S1.
Validation of the findings with Sanger sequencing
After filtering and annotation we selected 7 variants for
Sanger sequencing. Five of them (rs11579366, rs1990236,
rs176037, rs10653661, rs3803264) were typical for optimal
responders, two (rs3099950, rs9471966) – for failures.
Sanger sequencing confirmed WES findings except one
discordant result. Sanger sequencing detected heterozy-
gote for rs10653661 in TOX3 in one failure previously re-
ported by WES as homozygous reference. Detailed
analysis of the WES reads revealed low coverage of this
particular locus and allelic variant (insertion of TTTCT)
was present in the only read. Obviously it was not re-
ported by automatic variant calling and it was not also
considered during manual verification with IGV. The only
read with mutation is always a very unreliable finding to
be considered as a real variant.
Discussion
Targeted tyrosine-kinase inhibitors dramatically changed
efficacy of CML treatment and overall survival rates.
However there are about 20 % of CML patients failing
to achieve optimal response to TKI therapy. In this work
we applied WES in order to find genomic variants which
could explain differences in TKI inefficacy. WES is very
popular in studying cancers including myeloid neoplasia,
however there are no published studies about the differ-
ences between groups of CML patients with optimal and
non-optimal response to standard TKI therapy [13]. This
approach has the benefits of the unbiased search of the
independent prognostic markers. CML patients receiving
TKI therapy were assigned to either optimal responders
or non-optimal/failures according to ELN criteria 2013.
WES was performed in 8 patients and paired recovered
samples. Bioinformatic analysis revealed classic long-tail
distribution of the genes according to the number of
variants found in them. Annotation of the top-100 mu-
tated genes (from 41 to 345 mutations per gene) re-
vealed that these genes are important for cellular
processes and functions connected with the activity of
the immune system. Knowledge about involvement of
specific pathways allows developing gene-expression
panels for signaling pathway profiling which may serve
as an independent molecular marker [14].
However our aim was to find direct single-gene variations
which can explain and predict response to the therapy.
Multiple approaches can be applied to prioritize possible
targets among thousands of SNVs found in individual
exomes. We focused on the possible prognostic effect and
expected to find variants with strong association with one
of the treatment outcomes. We filtered exonic variants (27
in optimal responders and 15 in failures) which were either
missense or otherwise potentially involved in gene func-
tioning. We selected either missense variants with predicted
damaging effect on protein function, or upstream/down-
stream regulatory variants. These manually confirmed vari-
ants in cancer-associated genes were selected for further
Sanger resequencing. Below we describe all genes with
found variants.
ANKRD35 (Ankyrin Repeat Domain-Containing Protein
35) is a protein coding gene. Genecards annotated in
October 2014 its association with chronic lymphocytic
leukemia. This gene is expressed in normal human tissues,
including bone marrow, whole blood and white blood cells
but nothing is known about its function and role in cancer
pathogenesis of its variants [15]. We found g.1:145562293
G>C substitution (rs11579366) in responders but not in
failures. This variant has different frequencies of alleles in
different populations. According to “The 1000 Genomes
Project (Phase 3)” the allele frequencies are G = 0.2912 in
GBR but G= 0.8802 in ACB (data obtained on April 28,
2015). It is a promising prognostic factor because with that
high population frequency we though found opposite homo-
zygotes in failures and optimal responders. This G>C substi-
tution has “probably damaging” PolyPhen score (0.993).
DNAH9 (Dynein, Axonemal, Heavy Chain 9) encodes
the heavy chain subunit of axonemal dynein, a large
multi-subunit molecular motor. DNAH9 interacts with
B-cell CLL/lymphoma 6 (BCL6). BCL6 keeps B-cells in a
proliferative state in the germinal center, and down-
regulation of BCL6 is required for B-cell maturation and
differentiation. The dysregulation of BCL6 is implicated
in lymphomagenesis [16]. A total of 28 records are avail-
able in ClinVar with different variants of DNAH9 found
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in melanoma and lung cancer (April 28, 2015). Hetero-
zygous mutation in splicing site of DNAH9 (NM_
001372.3:c.10242+5G>A) was reported in one of the
cases with atypical CML [17]. We found a missense vari-
ant (rs1990236) g.17:11865462G>A. This variant has a
highly deleterious SIFT score (0.02). Its population fre-
quency is from as low as 0.07 in YRI up to 0.3 in PEL
being 0.2 in European populations.
MAGEC1 (Melanoma Antigen Family C, 1) is a pro-
tein coding gene associated with myeloma [18], digestive
tract carcinomas [19], glioblastoma [20] and melanoma
[21]. It is a member of the melanoma antigen gene
(MAGE) family. The proteins of this family are tumor-
specific antigens that can be recognized by autologous
cytolytic T-lymphocytes [22]. MAGEC1 helps cancer
cells in multiple myeloma to escape from immune-
surveillance, and its expression stimulates proliferation
of cancer cells [23]. The variant we found (rs176037) is
the g.X:140993642 C>T substitution and it has a deleteri-
ous SIFT score of 0.01. T allele frequency is about 0.5 in
European populations.
We also chose variant not previously described in
databases even if they did not influence the coding se-
quence directly. TOX3 (High Mobility Group Box Family
Member 3) is the protein coding gene. It contains a
HMG-box, and may bend and unwind DNA and modify
chromatin structure. Its high expression is associated
with poor prognosis in breast cancer [24]. Its variant
rs3803662 is associated with breast cancer [25] and mul-
tiple primary cancers [26]. TOX3 protects against cell
death by inducing antiapoptotic and repressing pro-
apoptotic transcripts. It stimulates transcription from
the estrogen-responsive or BCL-2 promoters. Among
optimal responders we found one homozygote and other
heterozygotes for rs10653661 – insertion of 5 nucleo-
tides in 3′-UTR g.16:52472421_2insTTTCT. This inser-
tion was not described in dbSNP135 which we used for
annotating variants before their filtration. And we chose
this variant as a new, not previously described finding.
This variant got its accession in dbSNP141 and popula-
tion frequencies are now available for it: from 0.24 in
CDX to 0.85 in YRI with 0.42–0.44 in Europeans. The
gene plays an important role in cellular processes in-
volved in cancer and its variants are associated with dif-
ferent cancers and diseases.
We also filtered homozygotes present in all optimal re-
sponders while all failures were wild-type homozygotes.
One of the variants was annotated as upstream gene
variant in THSD1 (Thrombospondin, Type I, Domain
Containing 1). It is a surface marker of hematopoietic
progenitors and endothelial cells [27]. THSD1 is methyl-
ated and down regulated in colorectal cancer [28] and
esophageal squamous cell carcinoma. In all optimal re-
sponders we found rs3803264 in a homozygous form
(AA) while all failures were wild-type homozygotes
(GG). This g.13:52971893G>A substitution is synonym-
ous in most of the THSD1 transcripts (NM_018676,
NM_199263), but NM_018676 can generate a shorter
protein (uc010tgz.2 length = 473 instead of uc001vgo.3
length = 852) in which case the variant is considered as
upstream gene variant. It has a high population fre-
quency of 0.65 in Europeans.
All the above described variants were present in the
same genotype in paired samples of optimal responders
before the beginning and after 6 months of TKI therapy.
This is why we consider these variants to be present in
the constitutive genome but not leukemic-specific som-
atic mutations.
In failures we found only two variants following the same
criteria as described above for the optimal responders.
MORN2 (Membrane Occupation and Recognition Nexus
Repeat Containing 2) is a protein coding gene. There are
five MORN-repeat containing genes in humans. MORN
motifs are necessary for binding junctophilins to plasma
membrane and endoplasmic reticulum [29]. Human
MORN2 facilitates phagocytosis-mediated restriction of
Mycobacterium tuberculosis in macrophages and is im-
portant for LC3-associated phagocytosis [30]. MORN4 in-
teracts with class III myosins and may be transported to
filopodia of moving cells [31]. We found rs3099950 in het-
erozygous form in all failures but in none of the re-
sponders. This missense substitution g.2:39109558G>A
has been registered with different frequencies in popula-
tions from 0.0 in many to 0.18 in PJL and has the fre-
quency of ~0.14 in Europeans.
PTCRA (Pre T-Cell Antigen Receptor Alpha) encodes
a protein that is found in immature T-cells. PTCRA is
the member of the pre-T-cell receptor complex, which
regulates early T-cell development. This gene along with
many others undergoes subsequent demethylation, re-
methylation and repression in appropriate stages of dif-
ferentiation. PTCRA is required for T-cell receptor
rearrangement and after this stage of T-cell development
it needs to be silenced in mature CD4+ cells to avoid
MHC class I binding [32]. PTCRA is also a member of
NOTCH1 signaling pathway which is an important regu-
lator of T-cell differentiation [33]. It was shown that
PTCRA is expressed in acute promyelocytic leukemia sig-
nificantly [34]. All failures in our study were heterozygotes
for rs9471966 – g.6:42891022G>A substitution. It has both
SIFT and PolyPhen deleterious scores. Allele A has the
lowest frequency in CHS – 0.01 and the highest in ESN
0.44, and with ~0.25 in Europeans. We consider it to be a
good target for both prognostic purposes and explanation
of therapy failure.
All seven variants have high population frequency in
at least some populations. Since we are not looking for
the variants associated with CML but rather with its
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sensitivity to TKI treatment, high population frequency
of the potential markers and dramatic difference in their
frequency between optimal responders and failures is
very promising for finding a highly sensitive and specific
prognostic marker. We suggest that TKI therapy may be
more successful for patients carrying the following
markers all together or in some combination: rs11579366
(C/C or C/G), rs1990236 (G/A), rs176037 (T/T or C/T),
rs10653661 (A/ATTTCT or ATTTCT/ATTTCT), rs380
3264 (A/A) and reference variants for rs3099950 (G/G)
and rs9471966 (G/G). However real prognostic value of
these markers and their possible combinations can be
clarified only in further prospective studies.
Conclusions
In conclusion we performed whole exome sequencing of
8 CML patients. Four of them demonstrated optimal re-
sponse to standard TKI therapy and another 4 were con-
sidered as failures. We filtered out from whole exome
data 7 variants (6 SNVs and one 5 nucleotide insertion)
which reflect heterogeneity of treatment efficacy in pa-
tients with CML and may help to select patients with
primary resistance to TKI therapy. As far as genes with
the selected variants associate with other types of can-
cers and found variants have predicted damaging effect
their possible functional effect should be carefully stud-
ied. To further validate functional role and prognostic
value of the variants it is necessary to perform retro-
spective and prospective studies in groups of CML
patients.
Methods
Newly diagnosed patients with Ph+ CML in chronic
phase at diagnosis have been included in this study at
Federal State-Funded Institution National Research Cen-
ter for Hematology of the Ministry of Healthcare of the
Russian Federation (Moscow, Russia) starting from June,
2012. Peripheral blood samples were collected at diagno-
sis after signing informed consent “Exome and transcrip-
tome analysis of leukemic cells in chronic myeloid
leukemia”. The study was conducted according to the
provisions of the Declaration of Helsinki. All patients re-
ceived standard treatment with TKIs and were examined
at regular time periods – 3, 6, 9 and 12 months during
the 1-st year of observation. The examination included
clinical evaluation, complete blood count, cytogenetic
and molecular tests which measured BCR-ABL expres-
sion by quantitative PCR. Patients were assigned to the
groups of either optimal responders or failures according
to ELN recommendations 2013 [5]. For the purpose of
our study we evaluated response at 6 months. All fail-
ures were checked for the absence of mutations in the
ABL-kinase domain of the BCR-ABL by sequencing.
DNA extracted from blood samples was used for WES.
WES was performed using Ion Torrent Personal Gen-
ome Machine (Thermo Fisher Scientific, Waltham, MA,
USA) with 200 bp reads. Exome enrichment was per-
formed using Ion TargetSeq™ Exome Kit which captures
about 30,000 protein-coding and RNA genes and pre-
dicted microRNA-binding sites. Sequencing analysis was
done in Torrent Suite software v.3.6.2. Single nucleotide
variants (SNVs) were annotated with ANNOVAR [35],
Partek Genomics Suite (Partek, St. Louis, Missouri,
USA) and Variant Effect Predictor tool [36]. Variants
identified by whole exome sequencing, were validated by
Sanger sequencing. Methods in more details are de-
scribed in Additional file 1.
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